NRAS mutations are well-known drivers of oncogenesis and have been associated with hematologic malignancies, including juvenile myelomonocytic leukemia (JMML) and ALPS [37, 40]. This evidence concerns the gene NRAS and juvenile myelomonocytic leukemia.